scholarly journals Stem Cell Therapy in Children With Sensorineural Hearing Loss: A Narrative Review

2021 ◽  
Vol 9 (3) ◽  
pp. 219-228
Author(s):  
Mahbobeh Oroei ◽  
◽  
Mohsen Ahadi ◽  
Keyword(s):  
Hearing Loss ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Sensorineural Hearing Loss ◽  
Cell Transplantation ◽  
Narrative Review ◽  
Sensorineural Hearing ◽  
Human Umbilical Cord ◽  
Positive Effects ◽  
Relative Improvement

Context: One of the research areas is using stem cell transplantation for treating children’s sensorineural hearing loss. Preclinical studies and testing of the stem cell types have been performed in this field, and relative improvement has been achieved. Objectives: This narrative review has been prepared to study the advancements in hearing regeneration with stem cell transplantation. Data Sources: The English articles with full-text were searched in PubMed, Scopus, and Google scholar from 2000 to 2020 using keywords of sensory neural hearing loss and stem cell. Results: In 2018, the first human study was performed with stem cells from the human umbilical cord, which has promising results regarding the safety of the method and its positive effects on hearing. Conclusions: Autologous stem cell transplantation had induced relative improvement without serious adverse events in children with acquired sensorineural hearing loss. To obtain more evidence, further studies are required with larger sample sizes and in different patients groups.

Long-term health status of high-risk neuroblastoma survivors treated with high-dose chemotherapy and hematopoietic stem cell transplantation.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 10054-10054 ◽  
Author(s):  
Sandrine Haghiri ◽  
Chiraz Fayech ◽  
Christelle Dufour ◽  
Claudia Pasqualini ◽  
Stephanie Bolle ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Stem Cell ◽  
High Risk ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Second Cancers

10054 Background: Current treatment strategies including high-dose chemotherapy with stem cell transplantation rescue (HDC-SCT) have improved 5-year event-free survival for high-risk neuroblastoma (HRNB) patients, but with an increased risk of late treatment-related toxicities. Methods: Between 1980 and 2012, 439 children were treated for HRNB with HDC-SCT in Gustave Roussy (GR), among which 145 were alive and disease-free at 5-year post-SCT. Long-term health data have been collected for those 145 patients, prospectively within the long-term follow-up clinic in GR or retrospectively from pediatric consultations. Results: With a median follow-up post-SCT of 15 years (range 5-34), we observed 6 late relapses, 11 second cancers (including 3 papillary thyroid carcinomas; median delay = 20 years post-SCT [18-22]) and 9 deaths. Event-free and overall survival at 20-year post-SCT were 82% (95%CI = 70–90) and 89% (95%CI = 78–95), respectively. A second health event was observed in 135 patients (median = 3/patient), including 103 patients with at least 1 severe event (median = 1/patient). Cumulative incidence at 15-year post-SCT for second cancers is 4%, cardiac diseases 8%, thyroid 11%, renal 7%, hepatic focal nodular hyperplasia 14%, dental mal-development 70%, and severe hearing loss 20%. Height-for-age z-score was ≤-2 for 30 patients (21%) and ≤-3 for 12 patients (8%). After Busulfan-Melphalan conditioning regimen, 40/43 females and 33/35 males had a gonadal insufficiency. Conclusions: Long-term consequences of HRNB treatment including HDC are frequent and disabling, mainly due to hearing loss and gonadal insufficiency.

Sign in / Sign up

Export Citation Format

Share Document